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Aims: Non-enzymatic glycation of DNA both in vivo and in vitro results in generation of free radicals,
known as glycoxidation. Glycoxidation leads to structural perturbation of DNA resulting in generation of
neo-antigenic epitopes having implication in autoimmune disorders like diabetes mellitus. In this study
human placental DNAwas glycated with methylglyoxal (MG) and lysine (Lys) in the presence of Cu2þ and
its auto-antibody binding was probed in Type 1 diabetes patients.
Methods: Glycation was carried out by incubating DNA with MG, Lys and Cu2þ for 24 h at 37 C.
Carboxyethyl deoxyguanosine (CEdG) formed in glycation reaction was studied by LC-MS and the
pathway for Amadori formation was studied by ESI-MS techniques. Furthermore, binding characteristics
of auto-antibodies in diabetes patients were assessed by direct binding, competitive ELISA and band shift
assay.
Results: DNA glycation with MG, Lys and Cu2þ results in the formation of CEdG (marker of DNA glycation)
which was conﬁrmed by LC-MS. The intermediate stages of glycation were conﬁrmed by ESI-MS tech-
nique. Serum from diabetes patients exhibited enhanced binding and speciﬁcity for glycated DNA as
compared to native form.
Conclusions: Glycation of DNA has resulted in structural perturbation causing generation of neo-
antigenic epitopes thus recognizing auto-antibodies in diabetes.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.Introduction
Diabetes mellitus is a common endocrine disorder characterized
by hyperglycemia due to the deﬁciency of insulin or insulin resis-
tance [1]. Hyperglycemia has an important role in the pathogenesis
of diabetes complications by increasing glycation intermediates and
the gradual build-up of advanced glycation end-products (AGEs) in
body tissues [1,2]. Glycoxidation and AGEs are accompanied by
increased free radical activity that contributes toward the biomol-
ecular damage in diabetes. There is a considerable interest in re-
ceptors for AGEs (RAGE) found on many cell types, particularly
those affected in diabetes [3]. Recent studies suggests that inter-
action of AGEs with RAGE alter intracellular signaling, geneBY-NC-ND license (http://
).
Published by Elsevier Inc. All rightexpression, release of pro-inﬂammatorymolecules and free radicals
that contribute toward the pathology of secondary complications
[4]. Hyperglycemia has an important role in the pathogenesis of
long-term complications and diabetes patients with poor blood
glucose control are particularly at risk [4]. Furthermore, complica-
tions appear to affect organs where cells do not require insulin for
glucose uptake, such as those of the nervous system, heart, kidneys
and small blood vessels [1]. As a consequence, these cells have high
concentrations of intracellular glucose during hyperglycemia. The
precise role of hyperglycemia in the pathogenesis of long-term
complications is still unclear. However, it is very well reported
that under hyperglycemic condition the level of methylglyoxal
(MG) increases 5e6 fold in the patients suffering from diabetes [5].
Moreover, the concentration of MG in human lenses is normally
about 20 times higher than in plasma [6]. It has been shown that
physiological levels of MG can induce DNA cleavage and ROS gen-
eration and decrease cellular adhesion in mononuclear cells [7].
Thus, MG has direct role in the initiation and progression of the
glycation reaction.s reserved.
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well as compounds related to sugars such as ascorbic acid, MG,
glyoxal and 3-deoxyglucosone etc. into biological macromolecules
such as DNA [8]. The free carbonyl groups of the sugar and related
moieties react with the free amino residues of the macromolecules
in a series of chemical processes known as Maillard reaction.
Initiation of glycation occurs by the formation of acid-labile Schiff
base adducts which undergoes Amadori rearrangements into more
stable products [9]. The early glycation products undergo slow
transformation to yield the irreversible AGEs. These reactions have
recently attracted signiﬁcant attention because of their association
with free radicals, which play roles in the development of cancer,
diabetes, heart disease, cataract, atherosclerosis and neurodegen-
erative disorder. Previous investigations by several scientists using
biochemical and molecular biological methods have shown that
DNA structure and function are affected by the addition of sugars,
resulting in deleterious modiﬁcations and mutations [10e12].
In the present study commercially available human placental
DNA was glycated as described previously [13]. The structural
changes induced in the DNA macromolecule by MG and Lys in the
presence of Cu2þ have been studied extensively. The adduct
formed by MG-Lys-Cu2þ system to human DNA was probed by LC-
MS technique. Moreover, the ESI-MS technique is also employed to
see the glycation intermediates formed in the DNA glycation.
Furthermore, the glycated DNA was used as an antigen for
detecting anti-DNA antibodies in sera of type 1 diabetes patients
by direct binding, competitive inhibition ELISA and the band shift
assay.
Materials and methods
Materials
Methylglyoxal (MG), anti-human IgG alkaline phosphatase con-
jugates, p-nitrophenyl phosphate, sodiumdodecyl sulfate, Tween-20,
Protein A-agarose (2.5 ml pre-pack column) and dialysis tubing were
purchased from Sigma Chemical Company, U.S.A. Dihydroxy acetone
(DHA) was from Merck, Germany. Lysine was from Sisco research
laboratory. Triton X-100 was procured from HieMedia. Trizma
base was from Spectrochem, Mumbai, India. ELISA plates (96 wells)
were purchased from NUNC, Denmark. Acrylamide, bisacrylamide,
ammonium persulphate and N,N,N0,N0-tetramethylethylenediamine
(TEMED) were from Bio-Rad Laboratories, U.S.A. EDTA, (disodium
salt), silver nitrate, sodium carbonate and sodium nitrite were from
Qualigens, India. All other reagents/chemicals were of the highest
analytical grade available.
Collection of sera
Fasting blood samples of type 1 diabetes patients, were ob-
tained from J.N. Medical College Hospital, A.M.U, Aligarh after the
informed consent. None of the patients with diabetes had other
autoimmune diseases. Speciﬁcally, there were no cases of lupus or
other connective tissue disorders. Normal human sera were ob-
tained from healthy subjects. Samples were collected in a glass test
tube and left to clot for 30 min at 37 C. Serum was separated by
centrifugation at 3000 rpm for 10 min. Serum samples were then
heated at 56 C for 30 min to inactivate complement proteins and
stored in aliquots at 20 C with 0.1% sodium azide as
preservative.
Puriﬁcation of human placental DNA
Commercially available human placental DNA was puriﬁed free
of proteins and single stranded regions as described previously [14].Modiﬁcation of human placental DNA by methylglyoxal (MG) and
lysine in presence of Cu2þ
Human placental DNA was modiﬁed by MG and lysine in the
presence and absence of Cu2þ as described by Ahmad et al. (2011)
[13]. 37.8 mM of human DNA was thoroughly mixed with MG
(40 mM), lysine (40 mM) and Cu2þ (300 mM) in 10 mM sodium
phosphate buffer, pH 7.4 containing 150 mM NaCl and incubated at
37 C for 24 h followed by extensive dialysis against PBS to remove
unbound constituents.
Synthesis of the standard, carboxyethyl deoxyguanosine (CEdG)
The synthesis of CEdG was carried out as described by Ashraf
et al. (2012) with slight modiﬁcations [15]. Brieﬂy, 50 mg of deoxy-
guanosine suspended in 1 ml of 100 mM phosphate buffer (pH,
7.4), was incubated with 100 mg of dihydroxyacetone at 70 C in a
shaking water bath. It got dissolved at 70 C in the course of
reaction after 24 h. CEdG was isolated by preparative HPLC using
50 mM ammonium acetate buffer solution and methanol as
eluents.
Detection of a glycated product, CEdG in modiﬁed human placental
DNA by LC-MS
An Agilent 1100 capillary HPLC System equipped with a Synergi
C18 analytical column was used for HPLC analysis of native and
modiﬁed analog of human placental DNA. General chromatographic
conditions were as follows: C18 column (2mm 150mmwith 4 mm
particle size); eluant A, 5 mM aqueous ammonium acetate buffer,
pH 7; eluant B, Acetonitrile (CH3N) gradient solution the CH3N
concentration was raised from 0 to 4.0% in the ﬁrst 5 min; from 4.0
to 6.5% over 30min; held at 6.5% for 5min, and then raised to 90% to
wash residual material off the column at a constant ﬂow rate of
500 mL/min. DNA bases were detected by diode array detector
(DAD) at 254 nm, their absorption maximum. LC-MS analyzes of
CEdG standard were carried out using a Micromass Quattro Ultima
Triple Quadrupole Mass Spectrometer interfaced to an Agilent 1100
capillary HPLC system.
Characterization of DNA-AGEs by electrospray ionization mass
spectrometry
An orthogonal time of ﬂight (TOF) mass spectrometer (Applied
Biosystems Mariner Atmospheric Pressure Ionization TOF Work-
station, Framingham, MA, USA) equipped with standard electro-
spray ionization source was used. The mass spectral data were
collected at positive ion polarity. Nitrogen was used as the nebu-
lizer, heater and collision gas. The sciex heater was set to 350 C and
the spray tip potential was set at 4000 V. The instrument was
outﬁtted with an integrated syringe pump with a dual syringe rack
for direct infusion onto the mass spectrometer. The mass spec-
trometry system was operated on full scan mode (m/z 100e1000).
Spectral acquisition was performed every 2 s and a total of ten
spectra were accumulated. The ﬁnal spectrum depicts an average of
4e6 scans.
Enzyme linked immuno-sorbent assay (ELISA)
ELISA was carried out on ﬂat bottom polystyrene plates as
described earlier [16,17]. Brieﬂy, microtitre wells were coated with
one hundred microliter of 2.5 mg/ml of DNA (in TBS, pH 7.4) and
incubated for 2 h at 37 C and overnight at 4 C. Each sample was
coated in duplicate and half of the plate, devoid of antigen, served
as control. The test-plate wells were emptied and washed thrice
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blocked with 150 ml of 1.5% non-fat dry milk (in TBS, pH 7.4) for 4e
5 h at 4 C followed by single wash with TBS-T. In direct binding
ELISA, antibodies were directly added into antigen-coatedwells and
incubated for 2 h at 37 C and overnight at 4 C respectively. The
wells were emptied and extensively washed with TBS-T. Anti-
immunoglobulin G alkaline phosphatase conjugate was added to
each well and incubated at 37 C for 2 h and then the plates were
washed thrice with TBS-T followed by a single wash with distilled
water. Para-nitrophenyl phosphate was added and the developed
color was read at 410 nm on a microplate reader. The results were
expressed as mean of difference of absorbance values in test and
control wells (Atest  Acontrol).Competition ELISA
The speciﬁc binding characteristics of antibodies were ascer-
tained in competitive binding assay [18]. Varying amounts of in-
hibitors (0e20 mg/ml) were mixed with constant amount of
antiserum or IgG. The mixture was incubated at room temperature
for 2 h and overnight at 4 C. Immune complex thus formed was
coated in the wells instead of the serum. The remaining steps were
the same as in direct binding ELISA.
Percent inhibition was calculated using the formula:
Percent inhibition ¼ 1

Ainhibited
Auninhibited

 100
Gel retardation assay
Antigen-antibody speciﬁcity was further conﬁrmed by the gel
retardation assay. A constant amount of DNA antigen (0.5 mg) wasFigure 1. a) Full scan LC-MS spectral analysis of synthesized CEdG standard. b) Full scan LC-
spectral analysis of hydrolyzed native human DNA (1 mg/ml).mixed with varying amounts of IgG [19] and incubated for 2 h at
37 C and overnight at 4 C. At the end of incubation, one-tenth
volume of sample buffer was added to antigeneantibody com-
plex and electrophoresed on 1% agarose gel in TAE buffer (pH 7.8)
for 2 h at 30 mA current. The gels were stained with ethidium
bromide (0.5 mg/ml) and visualized under UV light and
photographed.
Statistics
Data are presented as mean  SD. Statistical signiﬁcance of the
data was determined by student’s t-test (Statgraphics, Origin 6.1). A
value of p < 0.05 was considered statistically signiﬁcant.
Results
Glycation of human DNA
Human DNA (37.8 mM) was glycated with 40 mM MG, 40 mM
lysine and 150 mM Cu2þ for 24 h at 37 C. The structural perturba-
tion caused to the structure of the DNA macromolecule as a
consequence of the glycation reaction has been conﬁrmed in the
previously published literature [13,14].
Synthesis and characterization of N2-(1-carboxyethyl)-2-
deoxyguanosine (CEdG)
Synthesis of the standard, CEdG was performed as described
previously [15]. After ﬁnal preparation, CEdG was isolated by pre-
parative HPLC using 50 mM ammonium acetate buffer solution and
methanol as eluents. The elution of CEdG was obtained at a
retention time of 14.399 min when UV detector was used for the
experiment. However, deoxyguanosine (dG) gave elution at a
retention time of 9.1 min (data not shown).MS spectral analysis of hydrolyzed modiﬁed human DNA (1 mg/ml). c) Full scan LC-MS
Figure 2. a) Full scan ESI-MS spectral analysis of native human DNA (1 mg/ml) of HPLC resolved products. b) Full scan ESI-MS spectral analysis of modiﬁed human DNA (1 mg/ml) of
HPLC resolved glycated products.
Figure 3. Direct binding ELISA of serum antibodies from diabetes mellitus (DM) pa-
tients to native human DNA (,) and MG-Lys-Cu2þ glycated human DNA (-). Serum
from normal human subjects (NHS) served as control. The microtitre plates were
coated with the MG-Lys-Cu2þ glycated human DNA (2.5 mg/ml). p < 0.001 vs native
human DNA.
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in modiﬁed human DNA by LC-MS
The CEdG synthesized from dG was analyzed on mass spec-
trometer which showed a mass (m/z) of 338 signiﬁcantly different
from the 266 mass of dG (Fig. 1a). When modiﬁed DNA was
analyzed under identical conditions they showed mass value
matching with CEdG [15] (Fig. 1b). The MG-Lys-Cu2þ glycated-DNA
suggests CEdG formation andm/z value of 338was seen inmodiﬁed
human DNA [15] (Fig. 1b). However, analysis of native DNA suggests
no CEdG formation as evidence from ﬁgure (Fig. 1c).
Characterization of DNA-AGEs by electrospray ionization mass
spectrometry (ESI-MS)
In an attempt to conﬁrm the formation of Schiff base and
Amadori product in glycated DNA, mass spectrometry was used to
analyze the hydrolyzed glycated human DNA. Fig. 2 a&b show the
respective massespectral proﬁles of hydrolyzed native and MG-
Lys-Cu2þ glycated human DNA. The ion atm/z 341 is consistent with
a [Schiff base þ H]þ molecule resulting from the condensation re-
action of dG (Mr 285.26) with methylglyoxal (Mr 70.06) in a
dehydration reaction involving the loss of awater molecule. The ion
at m/z 679 is consistent with the formation of a [Schiff base þ H]þ
dimer product. Moreover, the ion at 268 is speculated to result from
the loss of a hydroxyl group from dG. Furthermore, the ionwithm/z
385 is assumed to be fragment formed by the degradation of MG
reacting with Schiff base product, or its enaminol or Amadori
intermediates.
Immunogenicity of modiﬁed DNA
The glycated DNA has been found to be a potent immunogen
inducing high titer (>1:12800), highly speciﬁc and non-
precipitating antibodies in experimental animals [13].
Binding of autoantibodies against native and MG-Lys-Cu2þ modiﬁed
human DNA in diabetes patients
The pilot study was performed to screen out the positive sera
samples (sera showing higher binding with the immunogen) from
type 1 diabetes patients. The sera were obtained from patients
attending J.N. Medical College and Hospital, A.M.U., Aligarh after
the informed consent. Our study comprised of 40 serum samples of
type 1 diabetes mellitus patients. Control serum samples from age
and sexmatched individuals were obtained from 20 normal healthy
subjects. All sera were diluted to 1:100 in TBS-T and subjected todirect binding ELISA on solid phase separately coated with equal
amounts of native and MG-Lys-Cu2þ modiﬁed human DNA. Out of
40 sera from type 1 diabetes, 27 samples (67.5%) showed higher
binding with the glycated DNA as compared to the native form
(Fig. 3). The serum samples which showed enhanced binding
(double or more than double binding) were considered for further
studies, while samples whose absorbance was less than or equal to
control were not included.
Immuno-cross reactivity of autoantibodies from diabetes type 1
patients
Competition ELISA was carried out to analyze the speciﬁc
binding of circulating autoantibodies in Type 1 diabetes patients
sera for native and MG-Lys-Cu2þ modiﬁed human DNA. In the 27
sera chosen from Type 1 diabetes patients, which showed enhanced
binding, the observed maximum inhibition with MG-Lys-Cu2þ
modiﬁed human DNA was in the range of 46.9e63.1% while with
native human DNA it ranged from 20.2 to 33%. Mean inhibition for
the entire sample tested with native human DNAwas 26.98  3.8%,
while for MG-Lys-Cu2þ modiﬁed human DNA, it was 54.95  5.4%.
However, under similar experimental conditions normal human
subjects showed mean inhibition of 32.5  2.1% with MG-Lys-Cu2þ
Table 1a
Competitive inhibition data of serum auto-antibodies in type 1 diabetes patients
Maximum percent inhibition at 20 mg/ml
Sera no Disease duration
(years)
Native human DNA
DNA
MG-Lys-Cu2þ
modiﬁed human
01 6 26.8 51.0
03 8 22.9 54.0
04 7 29.6 49.0
07 8 24.5 52.8
08 10 28.8 58.0
09 6 31.0 46.9
10 7 24.0 50.0
11 8 27.4 53.0
14 18 30.7 61.0
15 14 26.8 52.5
17 18 28.0 62.0
18 16 30.0 58.0
20 12 29.0 54.0
21 17 26.0 62.0
22 6.5 20.8 48.0
23 8 22.0 50.0
24 18 24.8 63.1
25 16 28.0 57.0
28 15 29.0 47.0
29 15 31.0 48.0
31 15 33.0 61.3
32 >20 26.0 62.0
34 15 27.8 55.7
36 10 24.0 49.1
37 16 24.7 62.8
38 15 20.2 58.6
39 15 31.7 52.8
Mean  SD 26.98  3.8% 54.8  5.4%
NHS 24.4  2.5% 32.5  2.1%
Themicrotitre plateswere coatedwithMG-Lys-Cu2þmodiﬁed human DNA (2.5 mg/ml).
NHS: Normal Human Sera.
Table 1b
Competitive inhibition data of IgG isolated from type 1 diabetes patients
Maximum percent inhibition at 20 mg/ml
Sera no Disease duration
(years)
Native human DNA
DNA
MG-Lys-Cu2þ
modiﬁed humans
03 8 28.0 62.1
07 8 29.6 60.7
08 10 31.7 65.1
14 18 33.8 68.0
15 14 30.1 61.9
17 18 28.0 69.0
18 16 33.8 64.1
21 17 35.6 65.8
24 18 31.0 68.1
25 16 31.0 69.6
31 15 35.0 68.1
32 >20 28.0 68.9
34 15 34.8 63.5
37 16 29.3 67.3
38 15 27.0 65.0
39 15 36.7 61.9
Mean  SD 31.46  3.2% 65.56  7.1%
NHS 26.8  2.6% 38.5  3.3%
Themicrotitre plateswere coatedwithMG-Lys-Cu2þmodiﬁed human DNA (2.5 mg/ml).
NHS: Normal Human Sera.
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24.4  2.5% mean inhibition. The above results have been sum-
marized in Table 1a.
Puriﬁcation of IgG from the sera of type 1 diabetes patient
IgG was isolated on a protein A-agarose column from selected
high binding sera of Type 1 diabetes patients. The puriﬁed IgG
eluted as a symmetrical single peak on the afﬁnity column. IgGFigure 4. Band shift assay of IgG isolated from diabetes type 1 patient serum with MG-Lys-C
were incubated with a constant amount of DNA (0.5 mg) for 2 h at 37 C and overnight at 4 
native (or modiﬁed) human DNA while lanes 2e5 contain native or MG-Lys-Cu2þ modiﬁedpurity was conﬁrmed by a single homogenous band on SDS-PAGE
under non-reducing conditions (data not shown).
Binding of IgG from different diabetes type 1 patients to native and
MG-Lys-Cu2þ modiﬁed human DNA
Puriﬁed IgG fromType1diabetespatients,were subjected todirect
binding ELISA, on a microtitre plate coated with native human DNA
and MG-Lys-Cu2þ modiﬁed human DNA to evaluate the amount
required for antigen saturation. The saturation for modiﬁed human
DNAwasobtainedat50mg/mlof IgG,while fornativehumanantigenic
saturation could not be ascertained because of its negligible binding.
Therefore, for Type 1 diabetes, IgG concentration was kept constant
(50 mg/ml) in all further experiments unless indicated. The binding
speciﬁcity of the isolated IgG, toward native and MG-Lys-Cu2þmodi-
ﬁed human DNA, was evaluated by inhibition ELISA. The IgG was
mixed with varying amounts of native or MG-Lys-Cu2þ modiﬁed
humanDNA(0e20mg/ml) and incubated for2hat37 Candovernightu2þ modiﬁed human DNA(a) and native human DNA(b). Varying concentrations of IgG
C. Electrophoresis was carried out on 0.8% agarose gel for 2 h at 30 mA. Lane 1 contains
human DNA with 20, 40, 60 and 80 mg of IgG from type 1 diabetes patient.
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69.6% when modiﬁed human DNA was employed as inhibitor, while
with the native human DNA it varied from 27 to 36.7%; maximum
inhibitor concentration being 20 mg/ml in both the cases. Themean of
inhibitions for various sample tested with theMG-Lys-Cu2þmodiﬁed
human DNAwas 65.56  7.1%, while with native human DNA, it was
31.46 3.2%.However, under similar experimental conditions normal
human subjects showedmean inhibition of 38.5 3.3%withMG-Lys-
Cu2þmodiﬁed human DNA, while with native human DNA it showed
26.8 2.6%mean inhibition. Table 1b summarizes the inhibition data
of isolated IgG of diabetes Type 1 group.
Band shift assay
Band shift assay was performed for the visual detection of
interaction of native and MG-Lys-Cu2þ modiﬁed human DNA with
puriﬁed IgG from type 1 diabetes patients. Equal amount of native
and modiﬁed DNA samples were incubated with increasing con-
centrations of IgG for 2 h at 37 C and overnight at 4 C. This resulted
in a proportional increase in the formation of highmolecular weight
immune complexes as visualized by retardedmobility and gradually
increased band intensity near the wells in agarose gel electropho-
resis, exhibiting better recognition of the modiﬁed epitopes by the
IgG from diabetes type 1 patients (Fig. 4 a & b).
Discussion
Glycation adducts of DNA may have potential as biomarkers
since all nucleated cells contain the same DNA content and should
reﬂect the relative level of MG in the target tissue. Reaction of
double-stranded DNA with MG or glucose in vitro produces pri-
marily N2-carboxyethyl-20-deoxyguanosine (CEdG), suggesting to
be the likely major adduct formed in vivo [20,21]. This implies that
CEdG might be a useful biomarker for monitoring oxoaldehyde-
induced stress in response to enhanced glycolytic ﬂux or environ-
mental exposure to MG. The preparative HPLC was employed for
the synthesis of the standard, carboxyethyl deoxyguanosine
(CEdG). The LC-MS was performed to detect the glycated adduct,
CEdG formed with the double stranded human DNA. The acid hy-
drolyzate of MG-Lys-Cu2þ glycated human DNA showed an m/z
value of 338 in the negative ion mode, which is in conformity with
the m/z value for standard CEdG. This ﬁnding is consistent with an
earlier study from our group [15]. Since CEDG has been reported as
the major DNA adduct formed as a result of glycation, it could serve
as an effective biomarker for the detection of glycation events
taking place in our body. It has been reported that the reaction of
deoxy-guanosine (dG) with MG proceeds via Amadori pathway
[22]. In our case the ESI-MS, mass-spectroscopic data has shown
similar results, i.e., the reaction of human DNA with MG-Lys-Cu2þ
proceeds via the classic Amadori pathway and yields glycation-like
products similar to those generated between a nucleoside and a
carbohydrate. This is in conformity with the results we obtained for
ESI-MS. The ion at m/z 341, 679, 268 and 385 is consistent with a
[Schiff base þ H]þ, [Schiff base þ H]þ dimer product, dG-H2O and a
fragment formed by the degradation of MG reacting with the Schiff
base product, or its enaminol or Amadori intermediate respectively.
Increased glycation and, in particular, accumulation of tissue and
serum AGEs have an important role in the pathogenesis of diabetic
complications. The chemical nature of many AGEs, their synthesis
in vivo and their precise role in the pathogenesis of complications of
diabetes are under intense investigation [1]. Reactive dicarbonyl
compounds formed endogenously like, glyoxal, methylglyoxal (MG)
and 3-deoxyglucosone, are potent glycating agents having potential
role in diabetes and secondary complications associated with it [23].
Glycation by MG is increased disproportionately compared to theincrease in glucose concentration in experimental and clinical dia-
betes [5]. Recently, D-ribose too has gained signiﬁcanceprominence in
the glycation of DNA and low density lipo-proteinwhichmight result
in the pathophysiology of complications associatedwith diabetes and
atherosclerosis [24,25]. The presence of auto-antibodies tomore than
two dozen auto-antigens have been associated with diabetes type 1
disease, a majority of interest has been directed to islet cell auto-
antibodies (ICA), insulin auto-antibodies (IAA), glutamic acid decar-
boxylase (GAD) and tyrosine phosphatase-like IA-2 auto-antigen [26].
These auto-antibodies, combined with other metabolic and genetic
markers, are extremely effective for predicting eventual development
ofType1diabetes. Inviewof this, thepossible involvementofMG-Lys-
Cu2þ modiﬁed human DNA in diabetes mellitus Type 1 was probed.
The binding of circulating auto-antibodies from 40 Type 1 diabetes
patients and 20 healthy normal subjects to native and MG-Lys-Cu2þ
modiﬁed human DNAwas studied by direct binding ELISA. Of the 40
sera in Type 1 diabetes, 67.5% showed preferentially high binding to
MG-Lys-Cu2þmodiﬁed human DNA as compared to its native analog.
No appreciable binding either with native or MG-Lys-Cu2þ modiﬁed
human DNA was observed with serum antibodies from healthy
normal subjects. Competition ELISA results showed 22e33% inhibi-
tion in the type-I diabetes auto-antibodies binding to native human
DNA,whereas46.9e63.1% inhibitionwas observedwithMG-Lys-Cu2þ
modiﬁed human DNA. These results indicate appreciable recognition
of MG-Lys-Cu2þmodiﬁed human DNA by the auto-antibodies in dia-
betes (type-I) patients. The binding speciﬁcity of the isolated IgG, to-
wardnative andMG-Lys-Cu2þmodiﬁedhumanDNAwasevaluatedby
competition ELISA. Immunoglobulin G (IgG) from diabetic patients
(type-I) recorded an inhibition of 59%e69% with the MG-Lys-Cu2þ
modiﬁed human DNA, while with native human DNA it ranged from
27% to 36%. Appreciably high binding of afﬁnity puriﬁed IgG toward
MG-Lys-Cu2þmodiﬁed human DNA, is indicative of the generation of
antibodies against RCS modiﬁed epitopes on the DNA molecules in
diabetes. The strong binding of auto-antibodies from diabetes Type 1
patients to MG-Lys-Cu2þ modiﬁed human DNA points toward the
involvementofmodiﬁedbases and single strand regions in thedisease
process. The spontaneous production of auto-antibodies in Type 1
diabetes might be a result of the generation of the antigenic epitopes
on the DNA molecules as a result of hyperglycemic condition in the
disease. These epitopes are recognized as ‘non self’ by the body’s im-
mune system, leading to the induction of autoantibodies in diabetes
type 1 patients and projecting the glycated DNA as one of the factors
eliciting the immune response in diabetes. These autoantibodies may
serve as a biomarker for the disease. The presence of auto-antibodies
against MG-Lys-Cu2þ glycated human DNA in diabetes mellitus pa-
tients is suggestive of the involvement of reactive carbonyl species
generated epitopes in autoimmune response in diabetes. Alterna-
tively, the experimentally induced antibodies against reactive
carbonyl species modiﬁed macromolecules may be used for the
detection of modiﬁed epitopes in diabetes patients.
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